Pfizer Company Description

Pfizer is the largest pharmaceutical company in the world operating in the Healthcare sector. The company generated $58.99 billion in revenues in 2012 and its net income was $14.6 billion for the same year. Pfizer has been producing blockbuster drugs since 1950, the most profitable of which has been Lipitor, a cholesterol-lowering medicine. The company operates in five business segments which include Primary Care, Specialty Care and Oncology, Established Products and Emerging Markets, Consumer Healthcare and Animal Healthcare. Pharmaceutical products which are mainly under Primary Care generated 74% of the 2012 revenues. Animal Healthcare and Vaccines (which comes under Specialty Care) generated 7% of the revenues each in 2012 and Consumer Health and Alliances generated 6%. Read More: PFE

Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE

Pfizer Inc. announced today top-line results from a Phase 3B/4 study of RAPAMUNE® evaluating kidney transplant patients who transitioned from tacrolimus-based therapy to RAPAMUNE® 3 to 5 months after transplant. Pfizer Inc. (PFE), with a current value of $205.23B, started the session at $30.88. Shares have traded today between $30.88 and $31.12 per share with a trailing 52-week range being $23.55 to $31.40.

Pfizer (PFE) shares are currently priced at 14.21x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -11.36x earnings multiple for the same period.  And for income investors, the company pays shareholders $0.96 per share annually in dividends, yielding 3.10%.

According to a consensus of 17 analysts, the earnings estimate of $0.53 per share would be $0.06 better than the year-ago quarter and a $0.00 sequential decrease. What we find to be interesting is that the full-year EPS estimate of $2.18 is a $0.01 setback when compared to the previous year’s annual results. Read more

Pfizer Reports Limp Performance for 3Q

Pfizer Inc. (PFE), the largest drug maker in the US by sales, reported earnings for 3QFY13 on October 29. Revenues missed analyst expectations by $0.1 billion and fell to $12.6 billion. Revenues declined 9.5% year-over-year (YoY), due to increased competition from generic medicines, and because of a stronger dollar. The company lowered its revenue projection for FY13 to $50.8-51.8 billion.

Adjusted earnings per share increased 9.4% YoY to 58 cents, beating analyst estimates by two cents. The EPS beat was driven by cost cutting measures and a lower tax rate. However, expectations for diluted per-share earnings were narrowed and lowered from $3.07-3.22 to $3.05-3.15 for FY13. Read more.

Mylan Inc : Mylan, Pfizer to Pay $625,000 in Massachusetts EpiPen Settlement

Mylan Inc. (>> Mylan Inc) and Pfizer Inc. (>> Pfizer Inc.) will pay Massachusetts a total of $625,000 to settle a case over television ads for a device used to treat allergic reactions, the office of Massachusetts Attorney General Martha Coakley said Thursday.

The device, EpiPen, allows for self-injection of FDA-approved steroid epinephrine for emergency treatment of allergic reactions. Pfizer makes the devices, and Mylan markets them under a licensing deal. The television ad in question, which aired in April 2012, along with a similar print ad, misled consumers into thinking that only EpiPen can prevent allergic reactions, the Massachusetts office said.

The companies are required to submit new ad campaigns for EpiPen and EpiPen Jr. to the U.S. Food and Drug Administration for pre-review. Mylan also settled with Oregon over the ads, agreeing to pay $250,000, that state's Department of Justice said. Pfizer in December agreed to pay Oregon $1 million over the campaign. Read more

FDA Okays Pfizer s Embeda Extended Release Capsules and 2 Other Hot Stocks to Watch

Pfizer has announced that the FDA has given a nod t0 a Prior Approval Supplement for Embeda (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII. 

 

The Supplement included an update to the Embeda manufacturing process, addressing the pre-specified stability requirement that caused the voluntary recall of Embeda from the market in March 2011. Pfizer expects product availability in the second quarter of next year. Read more.